Yagüe-Caballero Carmen, Casas-Deza Diego, Pascual-Oliver Andrea, Espina-Cadena Silvia, Arbones-Mainar Jose M, Bernal-Monterde Vanesa
Gastroenterology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
J Clin Med. 2024 Aug 8;13(16):4657. doi: 10.3390/jcm13164657.
Metabolic-associated steatohepatitis liver disease (MASLD) currently impacts a quarter of the global population, and its incidence is expected to increase in the future. As a result, hepatocellular carcinoma associated with MASLD is also on the rise. Notably, this carcinoma does not always develop alongside liver cirrhosis, often leading to a more advanced stage at diagnosis. The challenge lies in accurately identifying patients who are at a higher risk to tailor screening processes effectively. Additionally, several therapeutic approaches are being explored to prevent hepatocellular carcinoma, although there are no universally accepted guidelines yet.
代谢相关脂肪性肝炎（MASLD）目前影响着全球四分之一的人口，并且预计其发病率在未来还会上升。因此，与MASLD相关的肝细胞癌也在增加。值得注意的是，这种癌症并不总是与肝硬化同时发生，常常导致在诊断时处于更晚期阶段。挑战在于准确识别出高风险患者，以便有效地调整筛查流程。此外，尽管尚未有普遍接受的指南，但正在探索几种预防肝细胞癌的治疗方法。
